IS7173A - Líffræðilegar afurðir - Google Patents

Líffræðilegar afurðir

Info

Publication number
IS7173A
IS7173A IS7173A IS7173A IS7173A IS 7173 A IS7173 A IS 7173A IS 7173 A IS7173 A IS 7173A IS 7173 A IS7173 A IS 7173A IS 7173 A IS7173 A IS 7173A
Authority
IS
Iceland
Prior art keywords
disclosed
cdr
antibody
antibody molecules
biological products
Prior art date
Application number
IS7173A
Other languages
English (en)
Inventor
George Popplewell Andrew
Peter Tickle Simon
Zinkewich-Peotti Karen
Kendall Morrison Robert
Original Assignee
Celltech R & D Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R & D Limited filed Critical Celltech R & D Limited
Publication of IS7173A publication Critical patent/IS7173A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IS7173A 2001-10-10 2004-03-05 Líffræðilegar afurðir IS7173A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124317.9A GB0124317D0 (en) 2001-10-10 2001-10-10 Biological products
PCT/GB2002/004619 WO2003031475A2 (en) 2001-10-10 2002-10-10 Antibodies against kdr, their production and uses

Publications (1)

Publication Number Publication Date
IS7173A true IS7173A (is) 2004-03-05

Family

ID=9923562

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7173A IS7173A (is) 2001-10-10 2004-03-05 Líffræðilegar afurðir

Country Status (24)

Country Link
US (2) US7452976B2 (is)
EP (1) EP1438340B1 (is)
JP (2) JP4323312B2 (is)
KR (2) KR101018908B1 (is)
CN (1) CN1568331A (is)
AT (1) ATE482234T1 (is)
AU (1) AU2002334135B8 (is)
BR (1) BR0212756A (is)
CA (1) CA2458464A1 (is)
CO (1) CO5580838A2 (is)
DE (1) DE60237778D1 (is)
DK (1) DK1438340T3 (is)
EA (1) EA010970B1 (is)
ES (1) ES2351208T3 (is)
GB (1) GB0124317D0 (is)
HU (1) HUP0401618A3 (is)
IL (1) IL160849A0 (is)
IS (1) IS7173A (is)
MX (1) MXPA04003274A (is)
NO (1) NO20040987L (is)
NZ (1) NZ532758A (is)
PL (1) PL208848B1 (is)
WO (1) WO2003031475A2 (is)
ZA (1) ZA200401910B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1648510B1 (en) 2003-07-22 2013-06-19 Bayer Pharma Aktiengesellschaft Rg1 antibodies and uses thereof
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP2371960A3 (en) * 2005-03-25 2012-01-11 National Research Council of Canada Method for isolation of soluble polypeptides
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8497072B2 (en) * 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
LT2125894T (lt) 2007-03-22 2019-03-25 Biogen Ma Inc. Prisijungiantys baltymai, įskaitant antikūnus, antikūno dariniai ir antikūno fragmentai, kurie specifiškai suriša cd154, ir jų panaudojimas
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
SI2238166T1 (sl) 2007-10-05 2014-03-31 Genentech, Inc. Uporaba protitelesa proti amiloidu beta pri očesnih bolezni
DK2398498T3 (en) * 2009-02-17 2019-01-07 Ucb Biopharma Sprl ANTIBODY MOLECULES WITH SPECIFICITY FOR HUMAN OX40
CN101531718B (zh) * 2009-04-22 2011-11-02 中国人民解放军南京军区军事医学研究所 抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用
BR112012006670B8 (pt) 2009-09-24 2022-03-03 Ucb Pharma Sa Célula bacteriana gram-negativa recombinante, e, método para produzir uma proteína recombinante
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
KR102023786B1 (ko) 2011-07-13 2019-09-20 유씨비 파마, 에스.에이. 재조합 dsbc를 발현하는 세균 숙주 균주
MX356412B (es) 2011-11-02 2018-05-29 Apexigen Inc Anticuerpos anti-kdr y metodos de uso.
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2013125891A1 (ko) 2012-02-24 2013-08-29 (주)알테오젠 시스테인 잔기를 포함하는 모티프가 결합된 변형항체, 상기 변형항체를 포함하는 변형항체-약물 접합체 및 그 제조방법
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
KR101569083B1 (ko) 2012-11-21 2015-11-16 주식회사 파멥신 Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물
JP7303182B2 (ja) 2017-04-21 2023-07-04 メリタス エルエルシー 糖尿病関連用途のための方法及び抗体
CA3113223A1 (en) 2018-09-19 2020-03-26 Totient, Inc. Cancer associated antibody compositions and methods of use
CN113454120A (zh) * 2018-12-20 2021-09-28 阿尔伯特爱因斯坦医学院 针对人免疫检查点CEACAM1（CD66a）的拮抗剂抗体及其制剂，试剂盒，和使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
JP4405597B2 (ja) 1997-06-18 2010-01-27 メルク エンド カムパニー インコーポレーテッド ヒト受容体型チロシンキナーゼｋｄｒ
AU3850299A (en) * 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
JP2002536968A (ja) * 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用

Also Published As

Publication number Publication date
JP4323312B2 (ja) 2009-09-02
PL370344A1 (en) 2005-05-16
EP1438340B1 (en) 2010-09-22
CN1568331A (zh) 2005-01-19
EA010970B1 (ru) 2008-12-30
US20090269840A1 (en) 2009-10-29
AU2002334135B2 (en) 2009-01-08
KR101018908B1 (ko) 2011-03-02
NZ532758A (en) 2008-04-30
DE60237778D1 (de) 2010-11-04
AU2002334135B8 (en) 2009-01-29
CO5580838A2 (es) 2005-11-30
WO2003031475A8 (en) 2004-10-14
KR20070116110A (ko) 2007-12-06
PL208848B1 (pl) 2011-06-30
US7452976B2 (en) 2008-11-18
NO20040987L (no) 2004-05-10
BR0212756A (pt) 2004-11-16
HUP0401618A3 (en) 2012-03-28
US20050181448A1 (en) 2005-08-18
US7842787B2 (en) 2010-11-30
GB0124317D0 (en) 2001-11-28
DK1438340T3 (da) 2010-11-22
IL160849A0 (en) 2004-08-31
WO2003031475A2 (en) 2003-04-17
ZA200401910B (en) 2005-03-09
EA200400519A1 (ru) 2004-12-30
CA2458464A1 (en) 2003-04-17
WO2003031475A3 (en) 2004-03-25
KR20040097983A (ko) 2004-11-18
ATE482234T1 (de) 2010-10-15
HUP0401618A2 (hu) 2004-11-29
JP2009108086A (ja) 2009-05-21
JP2005516590A (ja) 2005-06-09
EP1438340A2 (en) 2004-07-21
MXPA04003274A (es) 2004-07-08
ES2351208T3 (es) 2011-02-01

Similar Documents

Publication Publication Date Title
IS7173A (is) Líffræðilegar afurðir
LTPA2017043I1 (lt) Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
MY136603A (en) Biological products
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
SI2860192T1 (en) Generating and profiling fully human HuCAL GOLD-specific therapeutic antibodies specific to human CD38
EA200300246A1 (ru) Ген и белок, ассоциированные с шизофренией
WO2002093519A3 (de) Humane hochaffine antikörperfragmente gegen essentielle proteine (ns3) von hepatitis-c-virus